Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

mAbs

Showing results (1321-1330 of 1,779) with videos related to

Pageof 178
Sort By:
Mabs|April 7, 2016
A novel antibody discovery platform identifies anti-influenza A broadly neutralizing antibodies from human memory B cellsXiaodong Xiao, Yan Chen, Reena Varkey, et al.
Mabs|April 7, 2016
Evaluating imbalances of adverse events during biosimilar developmentAlicia M Vana, Amy W Freyman, Steven D Reich, et al.
Mabs|March 12, 2016
Comparison of newly developed anti-bone morphogenetic protein 4 llama-derived antibodies with commercially available BMP4 inhibitorsSilvia Calpe, Ana C P Correia, Maria Del Carmen Sancho-Serra, et al.
Mabs|July 26, 2013
Therapeutic antibodies and infectious diseases, Tours, France, November 20-22, 2012Guillaume Desoubeaux, Arnaud Daguet, Hervé Watier
Mabs|July 26, 2013
LC-MS characterization and purity assessment of a prototype bispecific antibodyR Jeremy Woods, Michael Hongwei Xie, Thomas Spreter Von Kreudenstein, et al.
Mabs|July 26, 2013
Loss of deep cerebellar nuclei neurons in the 3xTg-AD mice and protection by an anti-amyloid β antibody fragmentGisela Esquerda-Canals, Joaquim Marti, Geovanny Rivera-Hernández, et al.
Mabs|March 2, 2012
Influence of improved FcRn binding on the subcutaneous bioavailability of monoclonal antibodies in cynomolgus monkeysAmita Datta-Mannan, Derrick R Witcher, Jirong Lu, et al.
Mabs|March 2, 2012
Aglycosylated antibodies and antibody fragments produced in a scalable in vitro transcription-translation systemGang Yin, Eudean D Garces, Junhao Yang, et al.
Mabs|March 29, 2012
Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administrationYanan Zheng, Devin B Tesar, Lisa Benincosa, et al.
Mabs|March 29, 2012
The Cabilly patents: status quo and relevance for antibody companiesUlrich Storz
Pageof 178

Showing results (1321-1330 of 1,779) with videos related to

Sort By:
Pageof 178
Mabs|April 7, 2016
A novel antibody discovery platform identifies anti-influenza A broadly neutralizing antibodies from human memory B cellsXiaodong Xiao, Yan Chen, Reena Varkey, et al.
Mabs|April 7, 2016
Evaluating imbalances of adverse events during biosimilar developmentAlicia M Vana, Amy W Freyman, Steven D Reich, et al.
Mabs|March 12, 2016
Comparison of newly developed anti-bone morphogenetic protein 4 llama-derived antibodies with commercially available BMP4 inhibitorsSilvia Calpe, Ana C P Correia, Maria Del Carmen Sancho-Serra, et al.
Mabs|July 26, 2013
Therapeutic antibodies and infectious diseases, Tours, France, November 20-22, 2012Guillaume Desoubeaux, Arnaud Daguet, Hervé Watier
Mabs|July 26, 2013
LC-MS characterization and purity assessment of a prototype bispecific antibodyR Jeremy Woods, Michael Hongwei Xie, Thomas Spreter Von Kreudenstein, et al.
Mabs|July 26, 2013
Loss of deep cerebellar nuclei neurons in the 3xTg-AD mice and protection by an anti-amyloid β antibody fragmentGisela Esquerda-Canals, Joaquim Marti, Geovanny Rivera-Hernández, et al.
Mabs|March 2, 2012
Influence of improved FcRn binding on the subcutaneous bioavailability of monoclonal antibodies in cynomolgus monkeysAmita Datta-Mannan, Derrick R Witcher, Jirong Lu, et al.
Mabs|March 2, 2012
Aglycosylated antibodies and antibody fragments produced in a scalable in vitro transcription-translation systemGang Yin, Eudean D Garces, Junhao Yang, et al.
Mabs|March 29, 2012
Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administrationYanan Zheng, Devin B Tesar, Lisa Benincosa, et al.
Mabs|March 29, 2012
The Cabilly patents: status quo and relevance for antibody companiesUlrich Storz
Pageof 178